login

Identifying biological markers of activity in human nociceptive pathways to facilitate analgesic drug development

PainPublished 24 October 2008Open access
Boris A. Chizh, Joel D. Greenspan, Kenneth L. Casey, Michael I. Nemenov, Rolf‐Detlef Treede
Citations26
View PDF

TL;DR

It is hypothesized that the preclinical to clinical transition can be facilitated by a rational use, in early drug development stages, of biological markers of activity in human nociceptive pathways, and that such markers could have translational value if adapted for animal studies to provide efficacy measures more clinically relevant than withdrawal reflexes.

Keywords

MedicineNeuroscience